From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.12
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (AR) transport (AR) enzyme binding (AR)
DNA binding (AR) cell-cell signaling (AR) cytoplasm (AR)
Anatomy Link Frequency
kidney 2
AR (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 17 85.88 High High
palliative 3 80.12 Quite High
Potency 7 24.64 Low Low
cytokine 7 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
dexamethasone 1 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 7 98.42 Very High Very High Very High
Disease 8 84.16 Quite High
Hypertrophy 6 83.28 Quite High
Prostate Cancer 43 81.36 Quite High
Malignant Neoplastic Disease 12 78.40 Quite High
Recurrence 5 73.28 Quite High
Metastasis 7 67.24 Quite High
Frailty 1 58.32 Quite High
Aging 1 55.52 Quite High
Reprotox - General 1 54 42.80 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Down-regulation of AR by estrogens is a common feature of AR, and E2 was shown to reduce both the AR mRNA and protein levels of stickleback kidney.
Negative_regulation (Down) of Negative_regulation (regulation) of AR in kidney
1) Confidence 0.28 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1192819 Disease Relevance 0.13 Pain Relevance 0
These results suggest that ARG1 expression may be more sensitive to AR inhibition than ARG2, whose expression was induced by the agnostic effect of the AR inhibitor.
Negative_regulation (sensitive) of Negative_regulation (inhibition) of AR
2) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2920336 Disease Relevance 0 Pain Relevance 0.04
This inevitable evolution led to new strategies being explored for delaying progression to androgen independence, which may involve targeting of anti-apoptotic factors, use of chemotherapy at the time of androgen ablation, or blockage or down-regulation of androgen receptor (AR) activity (Petrylak 2005).
Negative_regulation (down) of Negative_regulation (regulation) of androgen receptor associated with apoptosis
3) Confidence 0.12 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504071 Disease Relevance 0.98 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools